Recurrent COL7A1 Mutations in Japanese Patients with Dystrophic Epidermolysis Bullosa: Positional Effects of Premature Termination Codon Mutations on Clinical Severity  by Tamai, Katsuto et al.
LETTERS TO THE EDITOR
Recurrent COL7A1 Mutations in Japanese Patients with
Dystrophic Epidermolysis Bullosa: Positional Effects of
Premature Termination Codon Mutations on Clinical Severity
To the Editor:
Epidermolysis bullosa (EB) is a group of heritable mechano-
bullous disorders characterized by fragility of the skin and mucous
membranes (Fine et al, 1991; Christiano and Uitto, 1996a). A
special subset, the dystrophic forms of EB (DEB), is inherited either
in an autosomal dominant (DDEB) or in an autosomal recessive
(RDEB) fashion. Ultrastructurally, DEB is characterized by abnor-
malities in the anchoring fibrils, attachment structures extending
from the lower portion of the dermal–epidermal basement mem-
brane to the underlying dermis (McGrath et al, 1993). These
structures can be morphologically altered, reduced in number, or
entirely absent in patients with DEB.
Biochemical evidence has indicated that type VII collagen is the
major, if not the exclusive, component of anchoring fibrils (Sakai
et al, 1986; McGrath et al, 1993). This observation suggested that
type VII collagen and the corresponding gene, COL7A1, are the
candidate gene/protein systems for mutations in DEB (Uitto and
Christiano, 1992). Subsequently, a number of distinct genetic
lesions in COL7A1 have been demonstrated (Christiano and Uitto,
1996a, b; Hovnanian et al, 1997; Uitto et al, 1999).
Examination of the mutation database in DEB has suggested
that, in general, the mutations are family specific, with relatively
little evidence of recurrent mutations due to a founder effect or
‘‘hotspot’’ mutations (Uitto et al, 1999); however, careful examina-
tion of the database revealed that three mutations, 5818delC,
6573 1 1G→C, and E2857X occur in more than one unrelated
family and that these mutations are present only in individuals of
Japanese ethnic origin (Uitto et al, 1999). These observations
suggested therefore that these three mutations may be restricted to
the Japanese gene pool. In this study, we examined a cohort of 50
Japanese patients for the presence of these three mutations. All
patients had clinical and genetic features consistent with DEB,
including increased fragility of the skin and mucous membranes, and
characteristic extracutaneous manifestations, including esophagus
strictures and/or nail dystrophy, and the diagnosis was confirmed
by immunohistochemistry and/or electron microscopy.
Total genomic DNA was isolated from the patients’ peripheral
blood leukocytes by standard techniques. The three recurrent
mutations described in this study reside in exon 70, intron 81, and
exon 116, and the conditions for amplification of the corresponding
regions of the genomic DNA and for the heteroduplex analysis
have been described elsewhere (Shimizu et al, 1996; Christiano
et al, 1997; Tamai et al, 1997). All three mutations changed a
restriction endonuclease site that could be used for verification of
the mutations, as well as for screening for the presence of such
mutations in patients with DEB (Fig 1).
Screening of 50 unrelated Japanese patients with RDEB revealed
the presence of any of the three mutations in multiple individuals
(Table I). Specifically, mutations 5818delC and E2857X were
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present in nine individuals (18%) each, whereas the mutation
6573 1 1G→C was found in six individuals (12%). None of the
patients was homozygous for the respective mutation; however,
three patients were compound heterozygotes for two of these three
recurrent mutations, respectively (see below). Examination of the
current database consisting of 91 distinct COL7A1 mutations in
102 individuals with DEB failed to reveal the presence of these
three mutations in non-Japanese patients (Uitto et al, 1999).
Clinically, DEB manifests with a spectrum of phenotypic severity.
The most severe, recessively inherited form, the Hallopeau-Siemens
variant (HS-RDEB), manifests with extreme fragility of skin leading
to extensive scarring and fusion of the digits (pseudosyndactyly),
associated with extracutaneous manifestations such as esophageal
strictures and corneal erosions. Later in life, development of
aggressively metastasizing squamous cell carcinomas can lead to a
premature demise of the individual affected by HS-RDEB. In the
milder, so-called mitis forms, M-RDEB, protracted blistering
leads to less pronounced scarring with little or no tendency for
pseudosyndactyly; however, the clinical phenotype presents with
a continuum of severity, and some patients are classified as
HS/M-RDEB.
Three patients in which recurrent mutations in both alleles were
delineated were examined in detail.
Figure 1. Screening of Japanese DEB patients for recurrent
mutations by restriction endonuclease digestions. Specifically, the
5818delC mutation destroys a restriction enzyme site for MspI (Christiano
et al, 1995), whereas the mutation 6573 1 1G→C creates a new restriction
enzyme site for MspI (Tamai et al, 1997). The E2857X mutation destroys
a restriction enzyme site for MaeI (Tamai et al, 1997). The corresponding
PCR products were digested with these restriction enzymes under
conditions recommended by the manufacturer (Takara, Tokyo, Japan;
Boehringer-Mannheim, Indianapolis, IN). The digestion products were
examined on 3% agarose gels.
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Figure 2. Clinical features of Patients
1, 2, and 3. The positions of the premature
termination codon-causing mutations
(PTC) along the type VII collagen
molecule in the corresponding cases are
shown on the right-hand side. Open boxes
(u) correspond to the triple-helical regions,
whereas the solid bars (j) correspond to
noncollagenous domains within the type
VII collagen molecule. During diagnostic
work-up, indirect immunofluorescence of
the skin within a monoclonal LH7.2
antibody recognizing type VII collagen
showed clearly positive staining in Patient
1 (A) at the dermal–epidermal junction,
whereas the basement membrane zone
staining in Patient 2 (B) was markedly
attenuated. The staining in Patient 3 (C)
was entirely negative. Transmission
electron microscopy showed clearly
detectable, yet thin, anchoring fibrils in
Patient 1, whereas the anchoring fibrils in
Patient 2 were markedly reduced in
number. No anchoring fibrils were seen at
the dermal–epidermal junction in Patient
3 (not shown).
Table I. Recurrent mutations in Japanese patients
with RDEB
Mutation 5818delC 6573 1 1G→C E2857X
Number of patients (n 5 50) 9 6 9
Per cent 18 12 18
Non-Japanese RDEB 0 0 0
patients (n 5 120)
Patient 1 was a 39 y old Japanese man whose parents were
unrelated and clinically unaffected. The clinical details of this
patient consistent with the diagnosis of M-RDEB have been
reported elsewhere (Fig 2A; Tamai et al, 1997).
Patient 2 was a 40 y old Japanese male with generalized trauma-
induced blistering since birth. He had lost all fingernails and
toenails, and developed severe syndactyly (Fig 2B). The clinical
presentation of this patient was clearly more severe than in Patient
1, but not as severe as in Patient 3. Clinically, this patient was
classified as HS/M-RDEB.
Patient 3 was a 22 y old Japanese male with extensive and
extremely severe blistering of the skin since birth. No other member
of his family is affected, and his parents were not consanguineous.
Marked scarring and ulcers were observed all over his body. Diffuse
alopecia and almost complete syndactyly had developed (Fig 2C).
The clinical diagnosis was HS-RDEB.
Examination of the mutations in these three patients revealed
that Patient 1 was a compound heterozygote for 6573 1 1G→C/
E2857X, the two most 39 mutations of these three PTC mutations
(Fig 2A). In contrast, Patient 3 was compound heterozygote for
5818delC/6573 1 1G→C, the two most 59 mutations (Fig 2C).
Patient 2 with intermediate severity was compound heterozygote
for 5818delC/E2857X mutations (Fig 2B). These results clearly
indicate that mutation 6573 1 1G→C, when compared with the
more 59 mutation 5818delC, both superimposed on the common
mutation E2857X in the other allele, results in a milder phenotype.
On the other hand, mutation E2857X, by comparison with the
mutation 6573 1 G→C, when both combined with the mutation
5818delC in the other allele, results in a milder phenotype (Fig 2).
These observations clearly suggest that the positions of the PTC
mutations along the type VII collagen polypeptide can influence
the clinical severity, and in general, the spectrum of genetic lesions
in COL7A1 can underlie different clinical variants of DEB. The
combinations and types of mutations as well as their positions
along the type VII collagen molecules, superimposed on genetic
background of the affected individual, collectively reflect the
phenotypic variability observed in DEB.
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Native Type I Collagen is Not a Substrate for MMP2
(Gelatinase A)
To the Editor:
A recent JID paper by Herouy et al. (1998) presented some interesting
new data on lipodermatoschlerosis. Their interpretations of the data,
however, are based upon a single paper in the MMP literature (Aimes
and Quigley, 1995), which claims that MMP2 (gelatinase A) is an
interstitial collagenase, a claim that we have not been able to confirm.
We were the first laboratory to purify, characterize, and clone human
MMP2 (Seltzer et al, 1981; Collier et al, 1988). We found that this
proteinase had absolutely no activity against helical collagen. Native
helical collagen is defined by its resistance to trypsin cleavage and
characteristic viscosity in solution. Subsequent work from our labor-
atory has shown that MMP2 is an extremely opportunistic proteinase
against any collagenous sequence in which the helicity is not perfect.
For example, MMP2 cleaves helical type VII collagen within the
helical portion of the molecule, but in an area that has relaxed
helicity (Seltzer et al, 1989). When the Aimes and Quigley paper was
published we confirmed our original observations using pure TIMP-
free MMP2 and helical collagen shown to be trypsin resistant. Inter-
stitial type I collagen in which the helix was relaxed enough to render
it susceptible to trypsin digestion was indeed susceptible to digestion
by MMP2. Intact helical collagen was not. Ohuchi et al (1997) have
recently reconfirmed our original findings.
Cleavage of interstitial collagen by MMP1 yields two characteristic
fragments, which lose their helicity at 37°C and become soluble.
Therefore, solubilization of type I collagen is not indicative of MMP2
activity, but is of MMP1 activity. Herouy et al clearly show active
MMP1 in their western immunoblots, indicating that cleavage of
labeled type I collagen by their extracts can definitely occur.
It is important to point out that TIMP-MMP complexes have
been previously described, but are separated when subjected to SDS-
PAGE electrophoresis (Goldberg et al, 1989; Wilhelm et al, 1989).
The high molecular weight band shown in the immunoblots (Fig 2)
by Herouy et al (1998) either are a new type of complex, or represent
an artifact of antipeptide antibodies.
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Reply
Lipodermatosclerosis is characterized by distinct morphologic fea-
tures. Prominent perivascular fibrin cuffs and deposition of hemosid-
erin pigments due to red blood cell extravasation are major
tissue changes occurring in patients with severe chronic venous
insufficiency. Perivascular cuffs are highly organized structures
primarily composed of fibrin, laminin, fibronectin, tenascin and
type I and III collagens (Herrick et al, 1992). Fibrous scar tissue
associated with fragmentation of elastic fibers and loss of papillary
structures at the dermal–epidermal junction are further histologic
findings. The dermal–epidermal junction is built up by an extraord-
inarily complex network of interconnecting proteins such as differ-
ent collagen subtypes and laminin (Burgeson and Christiano, 1997).
To understand the molecular basis of these morphologic alterations
